JOHN P. NICHOLSON Jr., M.D.; E. DARRACOTT VAUGHN Jr., M.D.; THOMAS G. PICKERING, M.D.; LAWRENCE M. RESNICK, M.D.; JOSEPH ARTUSIO, M.D.; HOLLIS D. KLEINERT, Ph.D.; JORGE A. LOPEZ-OVERJERO, M.D.; JOHN H. LARAGH, M.D.
Prazosin was used to control the signs and symptoms of excessive alpha-adrenergic activity in four patients with pheochromocytomas. Long-term dosage requirements were predicted by the blood pressure response to a single 1-mg oral dose. However, surgical management of the pheochromocytomas was inadequate with prazosin alone, and intravenous phentolamine was required to suppress the pressor surges generated by the tumor during surgical manipulation and excision.
NICHOLSON JP, VAUGHN ED, PICKERING TG, RESNICK LM, ARTUSIO J, KLEINERT HD, et al. Pheochromocytoma and Prazosin. Ann Intern Med. ;99:477–479. doi: 10.7326/0003-4819-99-4-477
Download citation file:
Published: Ann Intern Med. 1983;99(4):477-479.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use